3 not yet recruiting, 2 recruiting, 1 active not recruiting, 1 completed. 6 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Not yet recruiting 3, Active not recruiting 1, Completed 1, Recruiting 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow Ribocure Pharmaceuticals AB: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| RBD1119 in Coronary Artery Disease (CAD) RBD1119, Placebo - Stable Coronary Artery Disease | Phase 2 | Not yet recruiting | Ribocure Pharmaceuticals AB | 200 | 2026-10-16 | 2026-10-20 |
| Vortosiran for VTE Prevention Vortosiran, Placebo - Venous Thromboembolism (VTE), Cancer | Phase 2 | Not yet recruiting | Ribocure Pharmaceuticals AB | 150 | 2026-10-01 | 2026-09-30 |
| Vortosiran in Atrial Fibrillation Vortosiran, Apixaban - Non-valvular Atrial Fibrillation (AF) | Phase 2 | Not yet recruiting | Ribocure Pharmaceuticals AB | 150 | 2026-10-01 | 2026-10-13 |
| First-in-human Trial of RBD2080 in Healthy Participants Placebo, RBD2080 - Healthy | Phase 1 | Recruiting | Suzhou Ribo Life Science Co. Ltd. | 24 | 2026-08-19 | 2026-10-13 |
| Phase 2 Trial Evaluating the Efficacy and Safety of RBD5044 in Patients With Mixed Dyslipidemia RBD5044, Placebo - Dyslipidemias | Phase 2 | Recruiting | Ribocure Pharmaceuticals AB | 120 | 2025-01-28 | 2026-09-10 |
| A Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of RBD4059 in Participants With Stable Coronary Artery Disease RBD4059, Placebo - Stable Coronary Artery Disease CAD | Phase 2 | Completed | Ribocure Pharmaceuticals AB | 30 | 2024-08-28 | 2026-05-27 |
| Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of RBD1016 in Participants With Chronic Hepatitis D RBD1016, Placebo - Chronic Hepatitis D | Phase 2 | Active not recruiting | Ribocure Pharmaceuticals AB | 14 | 2024-08-21 | 2026-10-15 |
Atrial Fibrillation (1) · Disease (1) · Dyslipidemias (1) · Hepatitis D, Chronic (1) · Neoplasms (1) · Pulmonary Embolism (1) · Venous Thromboembolism (1)
apixaban (1)
Sweden (5) · Poland (3) · Australia (1) · Bulgaria (1) · Denmark (1) · France (1) · Norway (1) · Romania (1)
Anders Gabrielsen, MD, PhD (2) · Anders Gabrielsen (1) · David Erlinge, MD, PhD (1) · Natasha Martin, PhD (1) · Sara Svedlund, MD, PhD (1)
2023 (1)